Equity
€92,443 ▼ 12.0%
MEDIDEVS paid out €59,000 in dividends. That is 127% of the 2025 profit.
MEDIDEVS
Lifetime
5 annual accounts with figures on one time axispeak €130,754 (2023)
€105,663▲ 43.2%
peak €93,651 (2023)
€46,440▲ 46.8%
peak €105,002 (2024)
€92,443▼ 12.0%
€26,887▲ 45.3%
Board1 name since 2020
1 directorJOOSTENS Dirk Geert Jan
Documentsfilings and deeds
15-06-202646 days before the deadline
2025micro format
Gross margin from €73,810 to €105,663Result from €31,635 to €46,440Dividend €59,000Debts from €18,507 to €26,887Cash from €62,195 to €23,893
Key points
from the 2025 annual accountsTurnover
≈ €260,000 estimated
The micro format states no turnover.
Position in the sector
€46,440
Higher net result than 83% of companies in other professional activities. Sector median €9,303 · 4,360 companies.
Checked score
96
Excellent
Financially stronger than 66% of micro companies in other professional activities (NACE 74)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 5,431 companies (NACE 74, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025lowest value
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: 0.1%▲ +0.1 percentage points vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026highest value
10-2026: < 0.1%▼ -0.1 percentage points vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Sector: Other professional, scientific and technical activities (NACE 74)
Liquidity: current ratio 4.22, cash €23,893, halved
Equity €92,443 (77.5% of total assets)
Figures for financial year 2025 (filed on 15-06-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 74, micro). It does better than 88% of them on solvency, 60% on liquidity, 88% on profitability and 29% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 26,972 companies had the same profile as MEDIDEVS has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.4%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of MEDIDEVS itself is lower: < 0.1% within 12 months. It rests on far more data about MEDIDEVS than the profile alone.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,972 companies, not a prediction for MEDIDEVS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €8,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 4.22 (6.43 in 2024), above the usual 1.5. Short-term debt is 20.5% and cash 20% of total assets. 22.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 15-06-2026, 46 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
46 days early
2024
66 days early
2023
33 days early
2022
on the day
2021
31 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 23 days before the deadline. In the sector (NACE 74), the median for financial year 2024 was 3 days before the deadline, and 38% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 June (4 of the last 5 accounts filed within 34 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0753600819
Incorporation
Founding capital of €10,000, 100 shares · Founder: JOOSTENS Dirk Geert Jan (comparant oprichter) · Appointment: JOOSTENS Dirk Geert Jan (director) · published on 04-09-2020 · Gazette deed
First establishment
Sperwerlaan 6, Grobbendonk
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MEDIDEVS Grobbendonk | €119,330 | €105,663 | 77.5% | - |
| Comontec Kortenaken | €115,893 | €108,616 | 38.4% | - |
| SHEQ Solutions Lier | €135,113 | €87,746 | 15.4% | 0 |
| ELBA Brasschaat | €129,034 | €78,908 | 40.8% | - |
| Dergonomics Mol | €129,018 | €95,628 | 86.9% | - |
| PHÉRA Antwerp | €125,909 | €126,090 | 83.2% | - |
| VP MED Zottegem | €139,458 | €125,166 | 87.7% | - |
These companies have the same main activity as MEDIDEVS: other professional, scientific and technical activities (NACE 74999). They are comparable in size and age: total assets between €116,000 and €139,000, founded between 2020 and 2022.
Official details
Source: KBO- Status
- Active since 02-09-2020Normal situation
- Activity
- Other professional, scientific and technical activitiesNACE 74999and 1 other
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2024
- Establishment unit
- 2.309.108.3582280 Grobbendonk, since 02-09-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 27-03-2026
Annual accounts 2025
- €119,330▼ 3.4%
- Employeeson 31-12-2025
- 1=
- Filing
- Filed on 15-06-2026, 46 days before the end of the filing period
Insights on MEDIDEVS
MEDIDEVS files the micro format. That format states no turnover. The gross margin rose from €25,600 in 2021 to €105,663 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MEDIDEVS
- What is the company number of MEDIDEVS?
- The company number of MEDIDEVS is 0753.600.819. The VAT number is the same number with BE in front: BE 0753.600.819.
- Where is MEDIDEVS based?
- The registered office is at Sperwerlaan 6, 2280 Grobbendonk.Company details
- What does MEDIDEVS do?
- According to the KBO register, the main activity is other professional, scientific and technical activities (NACE 74999).
- What is the legal form of MEDIDEVS?
- MEDIDEVS is a private limited company (BV).
- When was MEDIDEVS founded?
- MEDIDEVS was founded on 02-09-2020.
- Is MEDIDEVS still active?
- Yes, MEDIDEVS is an active enterprise in the KBO register.
- How many employees does MEDIDEVS have?
- MEDIDEVS had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does MEDIDEVS fall under?
- In its 2024 annual accounts, MEDIDEVS states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of MEDIDEVS?
- The turnover in financial year 2025 is ≈ €260,000. This figure is estimated from the gross margin of €105,663 and 2,203 comparable companies of the same size. It probably lies between €180,000 and €410,000. It is a rough estimate.
- Is MEDIDEVS profitable?
- In financial year 2025, MEDIDEVS made a profit of €46,440.
- Where can I find the annual accounts of MEDIDEVS?
- MEDIDEVS filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MEDIDEVS due?
- MEDIDEVS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.